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Background: Clozapine is highly effective in treatment-resistant schizophrenia, although, there remains significant
variability in the response to this drug. To better understand this variability, the objective of this study was to
predict brain extracellular fluid (ECF) concentrations and receptor occupancy of clozapine and norclozapine in
human central nervous system by translating plasma and brain ECF pharmacokinetic (PK) relationships in the rat
and coupling these with known human disposition of clozapine in the plasma.
Methods: Unbound concentrations of clozapine and norclozapine were measured in rat brain ECF using quantitative
microdialysis after subcutaneous administration of a 10 mg/kg single dose of clozapine or norclozapine. These data
were linked with plasma concentrations obtained in the same rats to develop a plasma–brain ECF compartmental
model. Parameters describing brain ECF disposition were then allometrically scaled and linked with published human
plasma PK to predict human ECF concentrations. Subsequently, prediction of human receptor occupancy at several
CNS receptors was based on an effect model that related the predicted ECF concentrations to published
concentration-driven receptor occupancy parameters.
Results: A one compartment model with first order absorption and elimination best described clozapine and
norclozapine plasma concentrations in rats. A delay in the transfer of clozapine and norclozapine from plasma to
the brain ECF compartment was captured using a transit compartment model approach. Human clozapine and
norclozapine concentrations in brain ECF were simulated, and from these the median percentage of receptor
occupancy of dopamine-2, serotonin-2A, muscarinic-1, alpha-1 adrenergic, alpha-2 adrenergic and histamine-1 for
clozapine, and dopamine-2 for norclozapine were consistent with values reported in the literature.
Conclusions: A PK model that relates clozapine and norclozapine disposition in rat plasma and brain, including
blood–brain barrier transport, was developed. Using allometry and published human plasma PK, the model was
successfully translated to predict clozapine and norclozapine concentrations and accordant receptor occupancy of
both agents in human brain. These predicted exposure and occupancy measures at several receptors that bind
clozapine may be employed to extend our understanding of clozapine’s complex behavioral effects in humans.
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Schizophrenia is a debilitating disorder that affects ap-
proximately 1% of the global population without regard
to race, sex or socioeconomic status [1]. Its onset occurs
typically in the late-teen years or early twenties and is
characterized by a high rate of morbidity and mortality.
Given these high personal and societal costs, investment
in research aiming at understanding the biology of the
disease, its genetic components and their interplay with
environmental factors, continues on many levels. Over
the past 50 years, pharmacotherapeutic support has been
instrumental in managing primarily the positive symp-
toms of schizophrenia. It hinges on suppression of a
central circuitry dysfunction that can be normalized by
antagonism of dopamine D2 receptors in the striatum
[2]. Introduction of clozapine, the first so-called atypical
antipsychotic approximately 25 years ago, represented a
significant advance in our understanding of schizophre-
nia from a systems biology perspective in that this drug
did not have the typical side effects of the first gener-
ation neuroleptics. This reduction in side effects was at-
tributed to higher 5HT2A than D2 receptor binding [3].
However, clozapine pharmacology is not limited to D2
and 5HT2A antagonism. Albeit unintentionally, the drug
binds to several other dopamine and serotonin receptor
subtypes, muscarinic M1/M4 receptors, and alpha-1 ad-
renergic receptors with pharmacologically relevant affinity
[4]. From a clinical perspective, this broad receptor cover-
age may account for clozapine’s unique superiority inFigure 1 Compartmental representation of clozapine and norclozpaine
and brain compartment of clozapine. Two compartments in green represente
CLclo/F (L/min) = apparent clearance of clozapine; Vclo-p/F (L) = apparent volum
of clozapine; Qclo/F. (L/min) = apparent intercompartmental clearance of cloza
Ktr1 (1/min) = transit rate constant of clozapine. Met (Norclozapine): CLclo-met/
(L/min) = apparent clearance of norclozapine; Vmet-p/F (L) = apparent volume
rate of norclozapine; Qmet/F (L/min) = apparent intercompartmental clearance
norclozapine in brain; Ktr2 (1/min) = transit rate constant of norclozapine.treatment resistant schizophrenia (TRS), even amongst
other atypical antipsychotics. From a research perspective,
the broad receptor coverage of clozapine conceivably
makes the drug a useful tool to advance our under-
standing of complex pharmacotherapy that incorporates
multiple interacting receptor systems.
The use of positron emission tomography (PET) im-
aging to measure receptor occupancy of clozapine and
other atypical antipsychotics in humans has been invalu-
able in demonstrating the importance of D2 and 5HT2A
receptor antagonism contributing to the efficacy of these
drugs [5-7]. However, broader application of this non-
invasive technique has been limited by the lack of li-
gands specific for other receptors to which clozapine has
affinity. In this regard, availability of other approaches
that are complementary to PET imaging would be use-
ful. One possibility is to link non-clinical measurements
of clozapine disposition in the brain with clinical studies
of clozapine systemic exposure using a translational PK
modeling approach. Prediction of clozapine CNS expos-
ure could then be related to its receptor binding kinetics
at multiple receptors to impart a virtual predicted phar-
macodynamic component to a model. This approach has
been used recently to predict CNS concentrations of
atomoxetine and duloxetine that were in the range of
receptor affinities associated with therapeutic doses [8].
In a related manner, a population pharmacokinetic-
pharmacodynamic (PK-PD) modeling approach was
used to predict D2 receptor occupancy of olanzapine inpharmacokinetics. Two compartments in blue represented the plasma
d the plasma and brain compartment of norclozapine. Clo (Clozapine):
e of distribution of clozapine in plasma; Kaclo (1/min) = absorption rate
pine; Vclo-b /F (L) = apparent volume of distribution of clozapine in brain;
F (L/min) = apparent clearance of clozapine to norclozapine; CLmet /F
of distribution of norclozapine in plasma; Kamet (1/min) = absorption
of norclozapine; Vmet-b/F (L) = apparent volume of distribution of
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of risperidone and its active metabolite paliperidone (9-
OH risperidone) [5-7,10]. These studies, as well as earl-
ier PK-PD models applied to other CNS drugs [11,12],
provide confidence in the ability of this approach to
deepen our understanding of drug action in human
brain.
A recent study measured clozapine and its N-desmethyl
metabolite, norclozapine, in extracellular fluid (ECF) of rat
medial prefrontal cortex using quantitative microdialysis,
and these results provided evidence of net efflux from brain
across the blood–brain barrier (BBB) [13]. This suggests
that plasma concentrations may not be a good predictor of
brain concentration for clozapine or norclozapine. There-
fore, prediction of clozapine exposure in the ECF of human
brain using a translational PK modeling approach could be
cross-validated against PET results at D2 and 5HT2A re-
ceptor occupancy in humans, and subsequently used toTable 1 Parameter estimates of final population pharmacokin
Parameters Estimates (RSE%) BAV (RSE
Clozapine
CLclo/F (L/min) 0.5(20.3)
Vclo-p/F (L) 19.4(40.3)
Kaclo (1/min) 0.00801(14.7)
Qclo/F (L/min) 2.01(40.8) 0.193(33.6
Vclo-b/F (L) 0.214 FIXED
Ktr1 (1/min) 0.0125(9.4) 0.05 (48.9
Fclo 1 FIXED 0.259(37.1
Norclozapine
Clclo-met/F (L/min) 0.055(24.8)
CLmet/F (L/min) 0.419(18.8) 0.111(74.8
Vmet-p/F (L) 2.95(38.6) 0.168(51.1
Kamet (1/min) 0.00277(31) 0.371(44.2
Qmet/F (L/min) 0.388(45)
Vmet-b/F (L) 0.25 FIXED
Ktr2 (1/min) 0.00517(12.3)
Fmet 1 FIXED
Residual error (proportional)
Parent-plasma 0.109(70)
Parent-brain 0.0367(27)
Metabolite-plasma 0.0762(24.1)
Metabolite-brain 0.014(18)
Clo (Clozapine): CLclo/F (L/min) = apparent clearance of clozapine; Vclo-p/F (L) = appa
rate of clozapine; Qclo/F (L/min) = apparent intercompartmental clearance of clozap
Vclo-b/F (L) = apparent volume of distribution of clozapine in brain; Ktr1 (1/min) = tra
Met (Norclozapine): CLclo-met/F (L/min) = apparent clearance of clozapine to norcloza
(L) = apparent volume of distribution of norclozapine in plasma; Kamet (1/min) = abs
clearance of norclozapine; Vmet-b/F (L) = apparent volume of distribution of norcloza
BAV = between animal variability.
RSE% = percent relative standard error.estimate clozapine receptor occupancy at the drug’s other
receptor targets for which PET tracers do not exist. Such
comprehensive PK-PD model could potentially support in-
dividualized dosing of clozapine to improve its efficacy and
CNS tolerability. It would also support research aimed at
discovering new approaches for the treatment of schizo-
phrenia in its different forms.
The purpose of this study was; (1) to build a PK model
that accounted for both plasma and brain concentrations
measured in rats; (2) to utilize this model to predict con-
centrations of clozapine and norclozapine in human brain.
This would allow for the prediction of expected receptor
occupancy in humans.
Methods
Study design
A single dose of clozapine (10 mg/kg) was administered
subcutaneously to four male Wistar rats with an averageetic model
Bootstrap analysis Median [5-95th percentiles]
%) Estimates BAV
0.463[0.358-0.661]
18.9[5.43-31.59]
0.00815[0.0051-0.0095]
) 2.08[0.58-3.43] 0.2[0.07-0.29]
) 0.0129[0.011-0.015] 0.047[0.0033-0.069]
) 0.243[0.062-0.35]
0.0584[0.04-0.0855]
) 0.43[0.33-0.61] 0.08[0.0038-0.18]
) 3.02[1.91-5.55] 0.149[0.000047-0.27]
) 0.00296[0.0015-0.0047] 0.319[0.065-0.54]
0.386[0.229-0.768]
0.00521[0.0045-0.0064]
0.084[0.029-0.19]
0.0371[0.023-0.055]
0.0714[0.051-0.11]
0.0133[0.0095-0.017]
rent volume of distribution of clozapine in plasma; Kaclo (1/min) = absorption
ine;
nsit rate constant of clozapine.
pine; CLmet/F (L/min) = apparent clearance of norclozapine; Vmet-p/F
orption rate of norclozapine; Qmet/F (L/min) = apparent intercompartmental
pine in brain; Ktr2 (1/min) = transit rate constant of norclozapine.
Figure 2 (See legend on next page.)
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Figure 2 Model diagnostic plots for clozapine. A and E: population prediction vs. observation plots for clozapine in plasma and brain ECF,
respectively, solid line is line of identity. B and F: individual prediction vs. observation plots for clozapine in plasma and brain ECF, respectively.
C and G: conditional weighted residuals vs. time for clozapine in plasma and brain ECF, respectively. D and H: conditional weighted residuals vs.
population prediction for clozapine in plasma and brain ECF, respectively.
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Netherlands). Three days prior to administration a mi-
crodialysis guide cannula was surgically implanted in the
medial prefrontal cortex; at the same time, a catheter for
blood sample collection was placed in the right jugular
vein and was exteriorized through an incision at the
top of the head. This vascular cannulation enabled an
equivalent volume of saline replacement for each blood
sample. A MetaQuant probe (6 mm, cellulose mem-
brane, BrainLink, The Netherlands) was inserted into
the guide cannula 24 hours prior to drug administration
to enable sampling of brain extracellular fluid (ECF).
Concentrations of clozapine and its N-desmethylated
metabolite, norclozapine, were measured in plasma and
brain ECF by HPLC with tandem mass spectrometry in
the positive ion mode as previously described [13]. For
each rat, the unbound concentrations in each compart-
ment were measured at 9 time points (0, 15, 30, 60, 90,
120, 240, 360 and 480 minutes) in plasma and 18 time
points (−30, 0, 30, 60, 90, 120, 150, 180, 210, 240, 270,
300, 330, 360, 390, 420, 450 and 480 minutes) in brain.
A single dose of norclozapine (10 mg/kg) was also ad-
ministered subcutaneously to another five male Wistar
rats with an average weight of 0.34 kg bought from the
same Harlan laboratories. Concentrations were mea-
sured in plasma and brain ECF, and the same time
points were used as those specified for clozapine.
Model development
Different model structures were initially evaluated using
the system dynamics software VENSIM (Ventana Systems,
Inc., MA, US). Thereafter a population approach was used
to describe the pharmacokinetics of clozapine and norclo-
zapine. Population PK parameters were estimated using a
nonlinear mixed effect modeling approach, as implemented
in NONMEM version 7.2 (Icon Development Solutions,
Hanover, Maryland) using Wings for NONMEM version
7 [14]. The first-order conditional estimation method
(FOCE) with interaction was used to estimate the struc-
tural PK parameters and the random effects parameters.
Model development was started with an assessment of
clozapine PK in plasma. One and two compartment
models with first order absorption for clozapine in plasma
were tested. A peripheral compartment structure was sub-
sequently implemented to represent the brain extracellular
fluid concentrations. The transfer characteristics of cloza-
pine between the plasma and the brain compartment were
evaluated using an intercompartmental clearance, CLin/CLout, as well as incorporating delay functions [15]. These
delay functions included a lag time and transit compart-
ment approaches. Once the structural model for clozapine
was established, the plasma compartment of norclozapine
was integrated and then connected to the brain compart-
ment. The same strategy was utilized in building the struc-
tural model for norclozapine concentrations that were
measured following norclozapine administration. Cloza-
pine and norclozapine concentration measurements were
then combined from the 9 rats and modeled simultan-
eously in the final structural model. The volume of distri-
bution of clozapine and norclozapine in brain were tested
with and without fixing this parameter to a literature re-
ported value [16]. A parallel metabolic pathway from the
extravascular space was also explored.
Between-animal variability (BAV) for PK parameters
was assumed to be log-normally distributed and evalu-
ated using an exponential model Pi = PTV x e
ηp where Pi
is the parameter estimate for the ith animal, and PTV is
the typical parameter value at the population level. The
variability between ith individual and population param-
eter values was described by ηp, which was identically
distributed with mean equal to 0 and variance, ωη
2 [17].
A combined additive and proportional model was first
used to describe the intra-animal variability. If one of
the elements of the model was found to be negligible
and not significant, it was then removed from the re-
sidual error model. Residual error parameters were as-
sumed to be normally distributed with mean equal to 0
and variance, σ2.Model selection and evaluation
Model evaluation was based on a likelihood ratio test using
the objective function value (OFV) provided by NONMEM.
The minimum OFV returned by NONMEM is approxi-
mately equal to −2 × log likelihood (−2LL) and served as a
guide during model design. A decrease in −2LL of 6.63
points for 1 degree of freedom was regarded as a signifi-
cant model improvement, corresponding to a p value of
0.01 for nested models. The final model was further exam-
ined using goodness-of-fit plots generated using R version
2.13 based on the conditional weighted residuals distribu-
tion and the predicted versus observed concentrations at
both the population and individual levels. Furthermore,
the final pharmacokinetic model was also evaluated using
a visual predictive check (VPC), and the uncertainty on
each parameter was determined using a non-parametric
Figure 3 (See legend on next page.)
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Figure 3 Model diagnostic plots for norclozapine. A and E: population prediction vs. observation plots for norclozapine in plasma and brain
ECF, respectively, dashed line is the line of identity. B and F: individual prediction vs. observation plots for norclozapine in plasma and brain ECF,
respectively. C and G: conditional weighted residuals vs. time for norclozapine in plasma and brain ECF, respectively. D and H: conditional
weighted residuals vs. population prediction for norclozapine in plasma and brain ECF, respectively.
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original dataset.
Human translation and expected receptor occupancy
After the pharmacokinetic model of clozapine in rat was
finalized, the PK model framework was adapted by scal-
ing PK parameters with allometric principles to predict
human concentrations in brain. The following exponents
were utilized scaling body weight to: clearance 0.75; vol-
ume of distribution 1; and first order rate constants 0.25
[18]. A 50% of conversion from clozapine to norcloza-
pine in humans was assumed in the model based on
prior reports [19-21], and this was implemented in the
simulated model assuming CLclo/F is equal to CLclo-p/F.
Model performance was evaluated by comparing model
simulated plasma concentrations to published human
clozapine plasma concentrations [22] at steady state follow-
ing 200, 300 and 400 mg daily doses. The published human
clozapine data were reported as total concentrations, andFigure 4 Visual predictive checks of clozapine in plasma and brain an
concentrations in plasma (A) and brain (B), and norclozapine concentration
clozapine. Norclozapine concentrations in brain following a 10 mg/kg subc
median of observed concentrations, the shape represents the 90% predicte
concentrations.these concentrations were converted to free concentra-
tion using 3% unbound fraction [23] prior to the com-
parison. After model validation, the simulated human
clozapine and norclozapine concentrations were used
to calculate the expected human receptor occupancy for
the following receptors: dopamine 2 (D2); serotonin 2A
(5-HT2A); muscarinic-1 (M1); alpha-1 adrenergic (α1);
alpha-2 adrenergic (α2); and histamine-1 (H1) using pub-
lished equilibrium dissociation constants (Kd) for cloza-
pine [24-26] and norclozapine (D2 only) [27].
Results
Rat population pharmacokinetics
A two-compartment model with first order absorption
best described clozapine pharmacokinetics in rats using a
central compartment for plasma concentrations and a per-
ipheral compartment for brain concentrations. Between
plasma and brain, an apparent delay in the distribution of
clozapine was identified. Several structural models wered norclozapine in plasma. Visual predictive check of clozapine
s in plasma (C) following a 10 mg/kg subcutaneous dose of
utaneous dose of clozapine were not measureable. Dashed line is the
d interval of the median, and the dots represent the observed
Figure 5 Visual predictive checks of norclozapine in plasma and brain. Visual predictive check of norclozapine concentrations in plasma
(A) and brain (B) following a 10 mg/kg subcutaneous dose of norclozapine. Dashed line is the median of observed concentrations, the shape
represents the 90% predicted interval of the median, and the dots represent the observed concentrations.
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ment model with two compartments best described flow
from plasma to brain, and inter-compartment clearance
described the return from brain to plasma (Figure 1).
Population pharmacokinetic estimates are given in Table 1.
Norclozapine exposures in plasma and brain following
clozapine administration were adequately described using
a similar structure, but with one fewer transit compart-
ment (Ktr2), which was estimated to be approximately 40%
of the clozapine value. The volume of distribution of clo-
zapine (Vclo-p/F) and norclozapine in brain (Vmet-p/F) were
fixed to the previously estimated values in the final model.
Although a significant reduction in the OFV was observed
when both parameters were estimated, they were esti-
mated with very poor precision. The elimination of cloza-
pine converted to norclozapine was CLclo-met at 0.055 L/
min, which is approximately 10% of total clozapine sys-
temic clearance. The NONMEM control stream with the
selected model is also included in the supplementary ma-
terial (Additional file 1).Figure 6 Simulated clozapine human unbound concentrations vs. pub
300 and 400 mg OID from 10 to 24 hours. The shape represents the 90
observed data.Figures 2 and 3 show the goodness of fit plots of the final
model for the parent drug and metabolite in plasma and
brain respectively. Population and individual predictions as
well as the conditional weighted residuals distribution are
shown in these figures. In the case of norclozapine, impre-
cision in population predicted plasma concentrations was
evident and is attributed to the inter-animal variability ob-
served in the context of the limited number of animals
available to support these predictions. The majority of the
fixed effects were estimated with less than 40% relative
standard error (Table 1). BAV was estimated for several of
the structural parameters and ranged from 5% (Ktr1) to 75%
(Clmet). Residual variability for clozapine in plasma and
brain were 10.9% and 3.7%, respectively, and residual vari-
ability of norclozapine in plasma and brain were 7.6% and
1.4%, respectively. VPC results are shown in Figures 4 and
5. The observed median (dashed black lines) concentrations
were adequately captured by the corresponding simulation
based 90% predicted intervals of median concentrations for
clozapine and norclozapine (shaped areas). Median, 5th andlished human concentrations at steady state in plasma with 200,
% predicted interval of the median and the dots represent the
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strap analysis of 1000 replicates are shown in Table 1.
Human translation
Simulated unbound clozapine concentrations in plasma
from 12 to 24 hours after administration were compared
with published human data and are shown in Figures 6A,
6B and 6C for 3 doses (200, 300 and 400 mg/day). Pre-
dicted occupancy of D2, 5-HT2A, M1, α1, α2 and H1 re-
ceptors were calculated using simulated unbound clozapine
and norclozapine (D2 only) brain concentrations for theseFigure 7 The predicted median percentage of receptor occupancy of D
The predicted median percentage of receptor occupancy of D2, 5-HT2A, M1,
predicted median percentage of receptor occupancy of D2 for norclozapine w
and dot line represent the predicted median percentage of receptor occupanthree daily doses. For clozapine, the predicted median per-
centage of receptor occupancy of D2 ranged from 6-42%,
9-52% and 11-59% for the 200, 300 and 400 mg daily doses,
respectively, across the inter-dose time interval. The me-
dian percentage of 5-HT2A receptor occupancy decreased
from 93% to 52%, 95% to 62% and 96% to 69% from 6 to
24 hours after 200, 300 and 400 mg daily doses, respectively.
For M1, α1 and H1 receptors, occupancies ranged from 74
to 99% across the dosage interval. In addition, the median
percentage occupancy of α2 receptors was predicted to be
in the range of 3-40% across the dosage interval. For2, 5-HT2A, M1, α1, α2 and H1 for clozapine and D2 for norclozapine.
α1, α2 and H1 for clozapine were shown in A to F, respectively, and
as shown in G between 6 to 24 hour after dose. The solid line, dash line
cy following 200, 300 and 400 mg daily doses, respectively.
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occupancy of D2 ranged from 1.1-17.3% across the dosage
interval. Receptor occupancy results across the dosage
interval are summarized in Figure 7.
Discussion
The model presented represents a unique PK model de-
veloped from directly measured concentrations of cloza-
pine and norclozapine in rat plasma and brain ECF. A
multiple transit compartment model was used to ac-
count for a delay in the transport of clozapine and nor-
clozapine from plasma to brain across the rat blood
brain barrier. Some evidence suggests that Pgp may be
involved in the process of clozapine transport [13,28]
across the blood brain barrier. The need to incorporate
transit compartments in the present model is consistent
with a Pgp role in clozapine transport across this barrier.
Using an animal model, drug exposure can be measured
by microdialysis at the target site. Based on a previously
published non-compartmental analysis, the ratio of AUC
between parent and metabolite in the rat indicated that
only about 10% of parent drug was eliminated through
metabolism [29]. This is consistent with the ratio of nor-
clozapine to clozapine clearance (Clclo-met = 9.91% of
Clclo). As the results revealed, even with relatively rich
sampling profiles, the uncertainty of some parameters,
in particular of between-animal variability, was large
likely because of the small number of animals in this
study.
Simulated human plasma concentrations were based
on previously published human plasma concentration
data [22]. The unbound plasma concentrations at steady
state after a range of doses overlapped with published
data corrected for the unbound fraction of clozapine
(3%) [23]. Subsequently, plasma exposures were linked
to the plasma – brain structural PK parameters, using
allometric scaling, that described clozapine and norclo-
zapine transport between plasma and brain in the rat to
ultimately predict human brain ECF exposure. This
population pharmacokinetic approach, based on a transit
compartmental approach as opposed to explicit assump-
tion of a Pgp role and its associated interspecies scaling,
enabled translational representation of the system across
species to predict human brain ECF concentrations. As
an atypical antipsychotic drug, clozapine targets D2 re-
ceptors as well as acts as an agonist or antagonist at sev-
eral other receptors found in the CNS. In order to get a
more complete profile of PK-PD linkage, percentage re-
ceptor occupancy of each receptor was calculated from
6 to 24 hour after three dosage levels. Our results show
that the median percentage D2 receptor occupancy was
in a range of 42% to 59% 6 hours after administration of
a daily dose of 200–400 mg. This range is congruent
with the 33% to 67% range reported by Nordström et al.[30], and agrees with the widely recognized understanding
of low D2 receptor occupancy of therapeutic doses of clo-
zapine relative to those obtained with therapeutic doses of
other antipsychotics (first and second generation). In
addition to D2, percent 5-HT2a receptor occupancy also
overlapped with the results of Nordström et al.
The proposed PK model thus demonstrated the ability
to extrapolate human systemic exposure to predict clo-
zapine brain concentrations and associated receptor oc-
cupancy profiles in humans at clinically relevant doses.
In addition, the model simultaneously captured parent
and metabolite in the system, which is relevant since
norclozapine also has activity at multiple receptors [31].
However, the model can be improved in the precision of
the PK parameter estimates by increasing the sample
size. With this limitation taken into consideration, the
model framework reported shows promise in predicting
clozapine receptor occupancy at multiple receptors in
human CNS, which can then be probed as a correlate to
response and/or toxicity.
Conclusions
We demonstrated that a translational PK modeling ap-
proach was able to predict clozapine and norclozapine
CNS exposures in humans, and these CNS exposures could
then be related to their receptor binding kinetics at mul-
tiple receptors. Such a modeling approach could be foun-
dational to the design of comprehensive PK-PD models
and extend our understanding of clozapine’s complex be-
havioral effects in humans.
Additional file
Additional file 1: NONMEM control stream.
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